Topic Listing for Dendreon

Abgenix Inc Acceleration Options
Accounting Records Accounting Stock-based Compensation
Accrued Liabilities Acquired In-process Research Development
Acquisition Corvas International Inc Active Immunotherapies
Active Immunotherapies Immunotherapy Targets Active Immunotherapy Approach
Active Immunotherapy Delivery Active Immunotherapy Production
Address Including Zip Code Registrants Principal Executive Offices Adjustments
Administration Adoption Incentive Plan
Aes Clean Technology Dendreon Corporation Aggregated Option Exercises Last Year-end Values
Agreement Agreements Governing Compensation
Amendment Amendment Agreement
Amendment Date Amendment Termination Duration
Amendments Amgen Fremont Inc
Annual Report Pursuant Securities Exchange Act 1934 Anti-kickback False Claims Laws Prescription Drug Marketing Act
Anti-serine Protease Monoclonal Antibodies Anti-takeover Provisions Charter Documents Delaware Law Stockholders Rights
Antigen Engineering Antigen Identification
Applications Payment Approval Dendreon Corporation 2009 Equity Incentive Plan
Assignment Audit Committee
Audit Committee Report Availability Amount Reimbursement Potential Products Manner Government Private
Availability Amount Reimbursement Product Candidates Manner Government Private Available Information
Background Background Purpose Duration
Base Basis Presentation
Beneficial Ownership Reporting Compliance Board Directors Committees Meetings
Board Directors Meetings Bonds
Broom Clean Condition Repair Requirements Business
Business Strategy Cancer Immunotherapies
Carbonic Anhydrase Antigen Carcinoembryonic Antigen Cea
Cash Equivalents Investments Cash Uses
Cash Uses Proceeds Certain Relationships Related Transactions
Certain Transactions Certification
Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act Changes Internal Control Over Financial Reporting
Changes Internal Controls Changes Work
Chief Financial Officer Claims Damages
Classification Directors Board Vacancies Clinical Trial Designs Discussed Authorities Prior Commencement Subsequently
Clinical Trial-d9901 Clinical Trial-d9902
Clinical Trial-d9905 Clinical Trial-p-11
Clinical Trial-p-16 Code Business Conduct
Codes Collaborations
Commercial Other Large-scale Manufacturing Experience Commercial Other Large-scale Manufacturing Experience Rely Party Manufacturers
Commercialization Product Candidates United States Requires Fda Approval Commitments Contingencies
Committees Board Directors Common Stock
Common Stock Reserved Comparison
Comparison Cumulative Total Return Investment Compensation Chief Executive Officer
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Directors
Compensation Philosophy Competition
Competitors Develop Market Products Less Expensive Effective Safer Compliance 409a Internal Revenue Code
Comply Extensive Regulation Costly Time Consuming Subject Unanticipated Composition
Concentrations Risk Conclusion
Conference Call Conference Call Details
Conference Call Information Conference Call Scheduled Tuesday 900 Est
Consent Independent Registered Public Accounting Firm Consolidated Statements Operations
Construction Agreement Construction Facility Expenses
Construction Progress Consultants
Contact Continue Build Portfolio Medically Important Oncology Product Candidates
Continuing Effect Agreement Contract Documents
Contract Manufacturers Subject Significant Regulation Respect Manufacturing Products Contractor Owner
Contractual Commitments Controls Procedures
Convertible Notes Cooperation Separate Contractors
Corporate Governance Committee Corporate Performance Chief Executive Officer Compensation
Corvas Acquisition Counterparts
Counting Votes Critical Accounting Policies Estimates
Currently Subject Certain Pending Litigation Stockholder Demand Government Currently Subject Certain Pending Litigation Stockholder Demand Similar
D9902b Impact Study Provenge Date
Debt Issuance Costs Definitions
Delaware Corporation Dendreon
Dendreon Announces Exercise Over-allotment Option Underwriters Public Offering Dendreon Announces Organizational Changes
Dendreon Announces Pricing Public Offering Dendreon Announces Senior Management Change
Dendreon Announces Strategic Realignment Focus Provenge Bla Commercialization Dendreon Corporation
Dendreon Corporation Reports 2005 Financial Results Dendreon Corporation Reports End 2004 Results
Dendreon Names Frohlich Vice President Clinical Affairs Dendreon Reports End 2005 Financial Results
Dendreon Signs Agreement Lease Manufacturing Facility New Jersey Dependent Single Source Vendors Some Components
Design Builder Owner Design Builders Fee
Design Compensation Programs Policies Develop Commercialize Provenge
Director Compensation Director Compensation Program
Director Compensation Table Director Independence
Directors Continuing Office Until 2006 Annual Meeting Directors Continuing Office Until 2007 Annual Meeting
Directors Continuing Office Until 2008 Annual Meeting Directors Continuing Office Until 2009 Annual Meeting
Directors Continuing Office Until 2010 Annual Meeting Directors Continuing Office Until 2011 Annual Meeting
Directors Executive Officers Registrant Discounts Rebates Refunds
Dn1924 Dn1921 Documents Confidentiality
Documents Incorporated Reference Dyax
Dyax Corp Ecitals
Elect Issue Additional Shares Common Stock Other Securities Elect Issue Additional Shares Common Stock Result Further
Election Directors Eligibility
Employee Benefit Plan Employee Stock Purchase Plan
Employees Employment Agreements
Employment Contracts Termination Change-in-control Arrangements Encounter Difficulties Enrolling Patients Clinical Trials Delayed Otherwise
Entrance Executive Consulting Agreement Entrance Executive Employment Agreement
Entry Material Definitive Agreement Environmental Safety Laws
Equal Opportunity Equity Compensation Plan Information
Equity Financings Equity Offering Proceeds
Equity Sales Estimates
Evaluation Disclosure Controls Procedures Even Approved Provenge Other Product Commercialize Market Later
Exact Name Registrant Specified Charter Except Historical Information Contained Herein News Release Contains
Except Per Share Amounts Executive Compensation
Executive Compensation Components Executive Compensation Plan Information
Executive Compensation Programs Design Considerations Executive Officers
Exhibits Existing Collaboration Agreements Not Achieve Desired Results Terminate
Expand Operations Commercialize Products Encounter Unexpected Costs Difficulties Expand Operations Commercialize Products Not Able
Expand Operations Commercialize Provenge Encounter Unexpected Costs Difficulties Explanatory
Exposed Potential Product Liability Claims Insurance Against Not Fail Enter Collaboration Agreements Product Candidates They Needed
Fail Enter Needed Collaboration Agreements Product Candidates Unable Failure Comply Foreign Regulatory Requirements Governing Human Clinical
Failure Retain Key Personnel Impede Ability Develop Products Fair Value
Fair Value Financial Instruments Fast Track Designation
Fast Track Designation Priority Review Fda Advisory Committee Determine Clinical Trials Data Regarding
Fda Approval Process Federal Income Tax Consequences
Financial Statements Financial Statements Exhibits
Financial Statements Supplementary Data Fold Detach Here
Foreign Tax Benefit Foreign Tax Benefit Expense
Form 10-k Form 10-q
Form Trade Contract Award Letter Former Name Address Change Since Last Report
Former Name Address Changed Since Last Report Forward Looking Statements
Forward-looking Statements Functions Authority
Genentech Genentech Inc
General General Administrative Expenses
General Information Shares Voted Via Internet Telephone General Provisions
Governing Law Government Regulation
Government Regulations Grants Plan-based Awards
Greement Guaranteed Maximum Price
Guidelines Visits Diosynth Facilities Hazardous Materials
Hazardous Materials Business Comply Environmental Laws Regulations Expensive Highlights Dendreons 2004 Accomplishments
History Operating Losses Expect Continue Incur Near Future History Operating Losses Expect Continue Incur Never Become
Host Conference Call Today 1100 Householding Proxy Materials
Http Bnymellonmobularnet Bnymellon Dndn Beneficial Http Investordendreoncom Edgarcfm
Http Investordendreoncom Governancecfm Http Wwwdendreoncom
Http Wwwsecgov Ignature Age Ollows
Immune System Immunotherapy Targets
Impact Individual Performance Compensation Impact Individual Performance Executive Compensation
Impairment Long-lived Assets Incentive Nonstatutory Stock Options
Income Taxes Increase Authorized Shares Common Stock
Indemnity Agreement Index
Index Consolidated Financial Statements Index Financial Statements
Industry Within Operate Business Subject Extensive Regulation Costly Information Regarding Independent Accountants
Information Regarding Independent Registered Public Accounting Firm Inspection Testing
Insurance Insurance Requirements
Intellectual Property Interest Expense
Interest Income Internet Availability Proxy Materials
Issuance Shares Pursuant Existing Future Collaborations Other Agreements Ithholding Bligations
Jones Kirin
Landlords Work Leases Credit Facility
Legal Construction Legal Proceedings
Leverage Core Competencies Liberal Recycling Provisions
Liens Claims Likely Require Additional Funding Future Access Capital Uncertain
Limitation Deduction Compensation Paid Certain Executive Officers Limitations Controls
Limited Commercial Other Large-scale Manufacturing Experience Liquidity Capital Resources
Live Access 2005 800 1100 Long-term Debt Capital Lease Obligations
Management Certain Security Holders Dendreon-certain Transactions Management Host Conference Call 1100
Management Host Conference Call 430 Managements Report Internal Control Over Financial Reporting
Manufacturing Commercial Infrastructure Market Acceptance Product Candidates Uncertain
Market Provenge Market Provenge Treatment Protocol
Market Registrants Common Equity Related Stockholder Matters Market Volatility Affect Stock Price Value Investment Common
Marketing Marketing Expenses
Materials Equipment Meetings
Methods Voting Changing Votes Minutes Reports
Monoclonal Antibodies More-
Multi-jurisdictional Regulations Including Those Establishing Ability Price Products Name
Name Person Filing Proxy Statement Other Registrant Near-term Prospects Highly Dependent Provenge Lead Product Candidate
Nearer-term Prospects Highly Dependent Provenge Lead Product Candidate Need Demonstrate Provenge Manufactured Facility Comparable Used Clinical
Need Demonstrate Provenge Manufactured New Facility Comparable Used Net Loss Per Share
Neuvenge Apc8024 Neuvenge Lapuleucel-t
New Accounting Standards Not Yet Adopted New Plan Benefits
Nominee Election One-year Term Expiring 2006 Annual Meeting Nominees Election Three-year Term Expiring 2008 Annual Meeting
Nominees Election Three-year Term Expiring 2009 Annual Meeting Nominees Election Three-year Term Expiring 2010 Annual Meeting
Nominees Election Three-year Term Expiring 2011 Annual Meeting Nominees Election Three-year Term Expiring 2012 Annual Meeting
Non-reimbursable Costs Nondisclosure
Nonstatutory Stock Options Not Intend Pay Cash Dividends Common Stock Foreseeable
Not Progress Programs Anticipated Stock Price Decrease Not Progress Programs Anticipated Stock Price Likely Decrease
Notice Annual Meeting Stockholders 2008 Notice Annual Meeting Stockholders 2009
Now Therefore Nuvelo
Ny-eso Objectives Compensation Programs
Objectives Executive Compensation Program Ongoing Regulatory Requirements
Operating Services Option Exercises Stock Vested
Option Exercises Stock Vested Table Option Grants 2004
Option Grants 2005 Option Renew
Organization Other Events
Other Expense Other Immunotherapy Targets
Other Matters Other Product Development Programs
Other Provenge Clinical Trials Other Provenge Clinical Trials Early-stage Prostate Cancer
Other Stock-based Compensation Outlook
Overview Page
Part Part Other Information
Payment Awards Performance Comparison Graph
Performance Measurement Comparison Pharmaceutical Industry Subject Significant Regulation Oversight United States
Pharmaceutical Medical Device Industries Subject Significant Regulation United Post-termination Compensation Benefits
Potential Payments Termination Potential Payments Termination Change-in-control
Power Attorney Preclinical Research Development Programs
Preferred Stock Preferred Stock Purchase Rights
Prepaid Manufacturing Costs Presented Asco Prostate Cancer Symposium
Price Controls Principal Accountant Fees Services
Principal Executive Officers Certifications Pursuant 302 Sarbanes-oxley Act Principal Financial Officers Certifications Pursuant 302 Sarbanes-oxley Act
Principles Consolidation Product Candidates
Product Candidates Overview Product Candidates Research Development
Production Supply Expenses Products Not Accepted Marketplace Therefore Able Generate Significant
Properties Property Equipment
Proportionate Basis Proposal
Proposal Nominees Election Directors Receive Greatest Number Votes Prostate Cancer
Protease Activated Therapy Pact Prodrugs Provenge
Provenge Apc8015 Provenge Clinical Trials Advanced Stage Prostate Cancer
Provenge Other Product Candidates Based Novel Technologies Raise Provenge Sipuleucel-t
Purpose Purpose Amendment
Purpose Effect Increase Amount Authorized Common Stock Pursuant 302 Sarbanes-oxley Act 2002
Quality Agreement Quantitative Qualitative Disclosures Market Risk
Quarterly Information Quorum Abstention Broker Non-votes
Ratification Independent Registered Public Accounting Firm Real Estate Taxes
Recent Accounting Pronouncements Recent Sales Unregistered Securities
Reclassification Reclassification Operating Expenses
Reclassifications Registration Rights Previously Granted Exercised Then Stock Price
Registration Sec Reimbursable Costs
Related Party Transactions Release Agreement
Rely Present Relationships Third-party Contract Manufacturers Limit Ability Rely Single Source Vendors Some Key Components Active
Replay Access Report Audit Committee Board Directors
Report Compensation Committee Board Directors Report Independent Registered Public Accounting Firm
Report Independent Registered Public Accounting Firm Internal Control Repricing
Require Additional Funding Future Access Capital Uncertain Required Elect Issue Additional Shares Common Stock
Research Development Research Development Expenses
Resources Authority Committee Restatement
Restatement Financial Statements Restructuring
Results Operations 2006 2005 Results Operations Financial Condition
Revenue Revenue Recognition
Revocability Proxies Risks Competition Factors
Risks Competitive Factors Risks Protecting Intellectual Property
Risks Protecting Intellectual Property Defending Legal Liabilities Risks Related Regulation Industry
Risks Relating Collaboration Agreements Risks Relating Collaboration Arrangements
Risks Relating Financial Position Need Additional Financing Risks Relating Manufacturing Activities
Risks Relating Manufacturing Activities Requirements Role Compensation Committee
Role Compensation Consultant Benchmarking Practices Role Compensation Consultant Benchmarking Practices 2008
Role Management Team Sarbanes-oxley Act 2002
Schedule Schedule Price
Schedule Process Consumables Schedule Work Early Occupancy
Scope Services Scope Work
Seattle 2008 Seattle 2009
Seattle Washington Securities Exchange Act 1934
Security Deposit Pledge Agreement Security Ownership Certain Beneficial Owners Management Related Stockholder
Seek License Acquire Complementary Products Technologies Selection Participants Determination Awards
Serine Protease Monoclonal Antibodies Shares Available Plan
Signature Signature Page Follows
Signatures Significant Agreements
Single-tenant Small Molecules
Solicitation Special Forward-looking Statements
Stock Option Exercises Holdings Stock Option Grants
Stock Option Plans Stock Ownership Retention Guidelines
Stock-based Compensation Stock-based Compensation Expense
Stockholder Communications Board Directors Stockholder Proposals
Stockholder Proposals 2006 Annual Meeting Stockholder Proposals 2007 Annual Meeting
Stockholder Proposals 2008 Annual Meeting Stockholder Proposals 2009 Annual Meeting
Stockholder Recommendations Board Nominees Stockholders Cordially Invited Attend Annual Meeting Person Plan
Stockholders Diluted Conversion Outstanding Convertible Notes Study Details
Subject Litigation Costly Defend Pursue Uncertain Outcome Subject Litigation Respect Ownership Intellectual Property Costly Defend
Subsequent Events Substantial Indebtedness Adversely Affect Financial Condition
Substitutions Summary Compensation
Summary Executive Employment Agreements Compensatory Terms Suppliers Raw Materials
Supplies Raw Materials Survival Rights
Table Contents Take Longer Complete Clinical Trials Project Not Able
Tax Consequences Tax Consequences Participants
Tax Regulatory Considerations Telomerase
Termination Termination Scenario Summary Tables
Termination Suspension Agreement Testing Particular Product Candidate Not Yield Successful Results
Trade Contracts Trademarks Tradenames
Transferability Trp-p8
Trp-p8 Monoclonal Antibody Trp-p8 Small Molecule
Unable Protect Proprietary Rights Defend Against Infringement Claims Upply Greement
Vote Important Votes Required
Voting Rights Outstanding Shares Voting Via Internet Telephone
Warrant Liability Warrants
Whereas Wilex
Withholding Taxes Xercise
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki